Dr. Mendiratta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106Phone+1 216-844-3951Fax+1 216-201-8160
Summary
- GU and Cutaneous Malignancies
Education & Training
- Cleveland Clinic FoundationFellowship, Experimental Therapuetics GU Fellow, 2017 - 2018
- Duke University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2002 - 2005
- Virginia Commonwealth University School of MedicineClass of 2002
- Virginia Commonwealth UniversityB.S., Biology, Magna Cum Laude with Honors, 1994 - 1998
Certifications & Licensure
- OH State Medical License 2011 - 2026
- NC State Medical License 2005 - 2018
- SC State Medical License 2009 - 2011
- IL State Medical License 2002 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient Choice Award Vitals, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- ASCO Merit Award ASCO Annual Meeting, 2008
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsATM/RB1 mutations predict shorter overall survival in urothelial cancer.Ming Yin, Petros Grivas, Hamid Emamekhoo, Prateek Mendiratta, Siraj M. Ali
Oncotarget. 2018-03-30 - 45 citationsNeoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoireAhmad A. Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni
Journal for Immunotherapy of Cancer. 2018-10-23 - 12 citationsLutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.Kanchi Patell, Matthew Kurian, Jorge A Garcia, Prateek Mendiratta, Pedro C Barata
Expert Review of Anticancer Therapy. 2023-07-01
Journal Articles
- Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal TherapyVadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate
- Genomic signatures associated with the Development, Progression, and Outcome of prostate cancerMendiratta P, Febbo, P, Molecular Diagnosis and therapy, 1/1/2007
- Treatment of Hairy Cell Leukemia with 2-Chlorodexoyadenosine (2CdA): Long term follow-up of the Northwestern University ExperienceChadha P, Rademaker AW, Mendiratta P, et al, Blood, 1/1/2005
Books/Book Chapters
Press Mentions
- Inside Sean Parker's $250 Million Bet to Cure CancerApril 13th, 2016
Professional Memberships
- Member
External Links
- KevinMDhttps://www.kevinmd.com/blog/post-author/prateek-mendiratta
- ASCO Connectionhttps://connection.asco.org/authors/Prateek%20Mendiratta,%20MD
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: